产品
编 号：F360208
分子式：C30H48O8
分子量：536.7
分子式：C30H48O8
分子量：536.7
产品类型
规格
价格
是否有货
100μg
询价
询价
结构图
CAS No: 445493-23-2
产品详情
生物活性：
Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis.
体内研究：
Pladienolide B (2.5-10 mg/kg; i.v.; daily for 5 days) has strong antitumor activities.Animal Model:Female or male BALB/c nu/nu mice (7 weeks of age) (PC-3, OVCAR-3, DU-145, WiDr, and HCT-116, BSY-1 xenografts)
Dosage:2.5, 5, and 10 mg/kg
Administration:I.v.; daily for 5 days
Result:Showed strong growth inhibitory or regressive activities against these xenografts.
体外研究：
Pladienolide B (0.1-2 nM; 24-72 hours) inhibits human cervical carcinoma cells viability.Pladienolide B (0.1-2 nM; 24-48 hours) reduces SF3b1 expression in human cervical carcinoma cells.Pladienolide B induces (0.1-2 nM; 24 hours) cell cycle arrest and apoptosis.
Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis.
体内研究：
Pladienolide B (2.5-10 mg/kg; i.v.; daily for 5 days) has strong antitumor activities.Animal Model:Female or male BALB/c nu/nu mice (7 weeks of age) (PC-3, OVCAR-3, DU-145, WiDr, and HCT-116, BSY-1 xenografts)
Dosage:2.5, 5, and 10 mg/kg
Administration:I.v.; daily for 5 days
Result:Showed strong growth inhibitory or regressive activities against these xenografts.
体外研究：
Pladienolide B (0.1-2 nM; 24-72 hours) inhibits human cervical carcinoma cells viability.Pladienolide B (0.1-2 nM; 24-48 hours) reduces SF3b1 expression in human cervical carcinoma cells.Pladienolide B induces (0.1-2 nM; 24 hours) cell cycle arrest and apoptosis.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备